GADETA

Gadeta is a research and development company that develops immunotherapies for cancer. It has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) with enhanced anti-cancer reactivity. Gadeta’s new cell-based anti-cancer product called T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs) has strong therapeutic potential for combating and eradicating both hematological and solid tumors. This approach utilizes high-affinity γδ TCRs expressed on αβ T cells with superior proliferation capacity.